These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9648739)

  • 1. Degradation of hammerhead ribozymes by human ribonucleases.
    Qiu L; Moreira A; Kaplan G; Levitz R; Wang JY; Xu C; Drlica K
    Mol Gen Genet; 1998 May; 258(4):352-62. PubMed ID: 9648739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNases involved in ribozyme degradation in Escherichia coli.
    Wang JY; Qiu L; Wu ED; Drlica K
    J Bacteriol; 1996 Mar; 178(6):1640-5. PubMed ID: 8626292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cleavage of full-length beta APP mRNA by hammerhead ribozymes.
    Denman RB
    Nucleic Acids Res; 1993 Aug; 21(17):4119-25. PubMed ID: 8371986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hammerhead ribozyme structure probed by cell extracts.
    Wang JY; Qiu L; Drlica K
    Gene; 1996 Nov; 181(1-2):117-20. PubMed ID: 8973318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity of hepatitis C virus RNA to the antiviral enzyme ribonuclease L is determined by a subset of efficient cleavage sites.
    Han JQ; Wroblewski G; Xu Z; Silverman RH; Barton DJ
    J Interferon Cytokine Res; 2004 Nov; 24(11):664-76. PubMed ID: 15684820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity.
    Sioud M
    J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of hammerhead ribozymes cleaving mdr-1 mRNA.
    Palfner K; Kneba M; Hiddemann W; Bertram J
    Biol Chem Hoppe Seyler; 1995 May; 376(5):289-95. PubMed ID: 7544982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A covalent crosslink converts the hammerhead ribozyme from a ribonuclease to an RNA ligase.
    Stage-Zimmermann TK; Uhlenbeck OC
    Nat Struct Biol; 2001 Oct; 8(10):863-7. PubMed ID: 11573091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages.
    Shimayama T; Nishikawa F; Nishikawa S; Taira K
    Nucleic Acids Res; 1993 Jun; 21(11):2605-11. PubMed ID: 8332458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High activity and stability of hammerhead ribozymes containing 2'-modified pyrimidine nucleosides and phosphorothioates.
    Heidenreich O; Benseler F; Fahrenholz A; Eckstein F
    J Biol Chem; 1994 Jan; 269(3):2131-8. PubMed ID: 8294467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes.
    Pieken WA; Olsen DB; Benseler F; Aurup H; Eckstein F
    Science; 1991 Jul; 253(5017):314-7. PubMed ID: 1857967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of hammerhead ribozymes for optimum cleavage of interleukin 6 mRNA.
    Hendrix C; Anné J; Joris B; Van Aerschot A; Herdewijn P
    Biochem J; 1996 Mar; 314 ( Pt 2)(Pt 2):655-61. PubMed ID: 8670082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors altering ribozyme-mediated cleavage of tumor necrosis factor-alpha mRNA in vitro.
    Kisich KO; Freedland SJ; Erickson KL
    Biochem Biophys Res Commun; 1997 Jul; 236(1):205-11. PubMed ID: 9223453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA.
    Karikó K; Megyeri K; Xiao Q; Barnathan ES
    FEBS Lett; 1994 Sep; 352(1):41-4. PubMed ID: 7925939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substitution of non-catalytic stem and loop regions of hammerhead ribozyme with DNA counterparts only increases KM without sacrificing the catalytic step (kcat): a way to improve substrate-specificity.
    Shimayama T; Sawata S; Komiyama M; Takagi Y; Tanaka Y; Wada A; Sugimoto N; Rossi JJ; Nishikawa F; Nishikawa S
    Nucleic Acids Symp Ser; 1992; (27):17-8. PubMed ID: 1283905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar cleavage efficiencies of an oligoribonucleotide substrate and an mdr1 mRNA segment by a hammerhead ribozyme.
    Holm PS; Dietel M; Krupp G
    Gene; 1995 Dec; 167(1-2):221-5. PubMed ID: 8566781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of ribozymes expressed using U1 and T7 vectors for the intracellular cleavage of ANF mRNA.
    De Young MB; Kincade-Denker J; Boehm CA; Riek RP; Mamone JA; McSwiggen JA; Graham RM
    Biochemistry; 1994 Oct; 33(40):12127-38. PubMed ID: 7918434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes.
    Kronenwett R; Haas R; Sczakiel G
    J Mol Biol; 1996 Jun; 259(4):632-44. PubMed ID: 8683570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.